Multiple studies and biosecurity frameworks confirm that commercial and regulatory standards require DNA synthesis providers to screen customer orders for dangerous pathogen sequences.
The retrieved papers provide extensive evidence that DNA synthesis providers screen orders for dangerous pathogen sequences, highlighting current tools, international screening baselines, voluntary industry practices, and evolving regulatory frameworks. No papers refute this claim.